B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PDE4D

MOLECULAR TARGET

phosphodiesterase 4D

UniProt: Q08499NCBI Gene: 514425 compounds

PDE4D (phosphodiesterase 4D) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PDE4D

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Thyroxine0.691
2vinpocetine0.691
3Abacavir0.691
4Adenosine Triphosphate0.691
5Amoxapine0.691
6Antazoline0.691
7Bromocriptine0.691
8Bucladesine0.691
9candesartan cilexetil [Supplementary Concept]0.691
10Cladribine0.691
11Clofarabine0.691
12Codeine0.691
13Crizotinib0.691
14Dextrothyroxine0.691
15Dihydroergotamine0.691
16Domperidone0.691
17Gestrinone0.691
18hydrocodone0.691
19Moricizine0.691
20Nortriptyline0.691
21Olmesartan Medoxomil0.691
22Papaverine0.691
23Terlipressin0.691
24Thyroxine0.691
25Troglitazone0.691

About PDE4D as a Drug Target

PDE4D (phosphodiesterase 4D) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented PDE4D interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PDE4D inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.